Document is current

Article History

Received: 7 October 2020

Accepted: 30 March 2021

First Online: 5 April 2021

Declarations

:

: Dr. Haen received speaker’s or consultancy fees from the following pharmaceutical companies: Servier, Novartis, and Janssen-Cilag. He is managing director of AGATE. He reports no conflict of interest with this publication. Dr. Hiemke has received speaker’s or consultancy fees from Janssen-Cilag, Lohmann Transdermal Systems and Servier. He reports no conflict of interest with this publication. Dr. Conca has served as a consultant for Lilly, Bristol-Myers Squibb, and Pfizer. He has served on the speakers’ bureau of Lilly, BMS, Astra Zeneca, Lundbeck, Italfarma, and Janssen. Dr. Gründer has served as consultant and advisory board member for the following companies and institutions: Allergan, Boehringer Ingelheim, Eli Lilly, IQWiG, Janssen-Cilag, Lundbeck, Otsuka, Recordati, SAGE and Takeda. He has received honoraria as a speaker for Gedeon-Richter, Janssen-Cilag, Lundbeck, Neuraxpharma, Otsuka and Recordati and funding for clinical trials from Boehringer Ingelheim, Lundbeck and Saladax. He is the founder and Shareholder of Brainfoods GmbH and Mind and Brain Institute GmbH. Dr. Paulzen has received speaker’s fees from Neuraxpharm, Lundbeck and Otsuka. He reports no conflict of interest with this publication. All other authors report no conflicts of interests.

: The data are available from the corresponding author upon reasonable request.